Often misunderstood, the new focus on prevention and population health within the NHS can help pharma become a critical part of a more holistic, outcomes-led strategy for local systems, argues Oli Hudson - Magazine Article - PharmaTimes
by Oli Hudson
https://www.pharmatimes.com/magazine/2021/december_2021/why_pharma_needs_to_understand_population_healthSteve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long Term Plan’s vision to deliver more preventative, joined-up services for key illnesses - Magazine Article - PharmaTimes
by Steve How and Oli Hudson
https://www.pharmatimes.com/magazine/2019/june_2019/a_new_approach_to_major_health_conditionsPaul Midgley and Oli Hudson, of Wilmington Healthcare, explore how the Long Term Plan has been driving transformation in the NHS this year - Magazine Article - PharmaTimes
by Paul Midgley and Oli Hudson
https://www.pharmatimes.com/magazine/2019/december_2019/2019_-_a_momentous_year_for_the_nhsOli Hudson, content director at Wilmington Healthcare, explores how the coronavirus pandemic is changing pharma’s relationship with the NHS - Magazine Article - PharmaTimes
by Oli Hudson
https://www.pharmatimes.com/magazine/2020/september_2020/customer_engagement_in_the_covid-19_recovery_eraAs an influential new series of quality improvement reports illustrate how the NHS is shifting its focus to population health, Oli Hudson explores the opportunities for pharma - Magazine Article - PharmaTimes
by Oli Hudson
https://www.pharmatimes.com/magazine/2021/november_2021/getting_it_right_first_time_pharmas_chance_to_shineWhile recent vaccine developments provide a glimpse of a post-COVID future, the ongoing impact of the pandemic on prescribing patterns is still being closely scrutinised. Oli Hudson looks at what the data tells us so far, and where things might go
by Oli Hudson
https://www.pharmatimes.com/magazine/2021/januaryfebruary_2021/covid-19_a_tough_pill_to_swallow_for_drug_prescribingHow will COVID-19 and the ongoing major reforms affect the way pharma relates to the NHS? Oli Hudson examines the five key factors likely to have the biggest impact in 2022 - Magazine Article - PharmaTimes
by Oli Hudson, content director at Wilmington Healthcare.
https://www.pharmatimes.com/magazine/2022/januaryfebruary_2022/the_new_nhs_landscape_is_pharma_ready_for_a_revolutionThe NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma - Magazine Article - PharmaTimes
by Steve How, Paul Midgley & Oli Hudson
https://www.pharmatimes.com/magazine/2018/december_2018/integrated_care_agenda_stimulates_seismic_change_in_2018The implications of adalimumab’s European patent expiry - Magazine Article - PharmaTimes
by Steve How, Paul Midgley & Oli Hudson
https://www.pharmatimes.com/magazine/2018/november_2018/biosimilar_adalimumab_a_landmark_for_nhs_medicines_optimisationWith crucial changes to funding models and new formulary arrangements emerging at system and place levels, Oli Hudson shares the latest intelligence on how the drug funding landscape will be affected by reforms, and how industry must adapt
by Oli Hudson
https://www.pharmatimes.com/magazine/2021/september_2021/are_you_ready_to_dive_into_a_new_era_for_medicines_funding
